{"component": "definition", "props": {"groups": [{"snippet": "means the sum of, without duplication, the following costs or expenses:", "snippet_links": [{"key": "sum-of", "type": "clause", "offset": [10, 16]}, {"key": "without-duplication", "type": "clause", "offset": [18, 37]}], "samples": [{"hash": "7mGg8LO0FCh", "uri": "/contracts/7mGg8LO0FCh#permitted-deductions", "label": "Share Purchase Agreement (LAVA Therapeutics NV)", "score": 36.7919235229, "published": true}, {"hash": "c1SLUxdpeDS", "uri": "/contracts/c1SLUxdpeDS#permitted-deductions", "label": "Contingent Value Rights Agreement (Concentra Biosciences, LLC)", "score": 36.6577682495, "published": true}, {"hash": "2jLWNe1lvAJ", "uri": "/contracts/2jLWNe1lvAJ#permitted-deductions", "label": "Contingent Value Rights Agreement (iTeos Therapeutics, Inc.)", "score": 36.6577682495, "published": true}], "size": 54, "hash": "87902f7b54a85b9a4097f1fc45f769fb", "id": 1}, {"snippet": "means the following deductions to the extent actually deducted by a Selling Entity from the gross invoiced sales price of the Product, or otherwise directly paid or incurred by the Selling Entity with respect to the applicable sale of the Product:", "snippet_links": [{"key": "to-the-extent", "type": "clause", "offset": [31, 44]}, {"key": "selling-entity", "type": "definition", "offset": [68, 82]}, {"key": "the-gross", "type": "clause", "offset": [88, 97]}, {"key": "price-of-the-product", "type": "clause", "offset": [113, 133]}, {"key": "the-selling", "type": "definition", "offset": [177, 188]}, {"key": "with-respect-to", "type": "clause", "offset": [196, 211]}, {"key": "sale-of-the-product", "type": "clause", "offset": [227, 246]}], "samples": [{"hash": "b6XpTDarHCH", "uri": "/contracts/b6XpTDarHCH#permitted-deductions", "label": "Contingent Value Rights Agreement (Miramar Labs, Inc.)", "score": 28.4442157745, "published": true}, {"hash": "9bYDb0PY8Ij", "uri": "/contracts/9bYDb0PY8Ij#permitted-deductions", "label": "Contingent Value Rights Agreement (Sientra, Inc.)", "score": 28.4442157745, "published": true}, {"hash": "aGRoNhuUCZs", "uri": "/contracts/aGRoNhuUCZs#permitted-deductions", "label": "Contingent Value Rights Agreement (Cubist Pharmaceuticals Inc)", "score": 24.7097873688, "published": true}], "size": 27, "hash": "1a8645f198e5ad7c9dbc37a4026d8aa0", "id": 2}, {"snippet": "means the sum of:", "snippet_links": [{"key": "sum-of", "type": "clause", "offset": [10, 16]}], "samples": [{"hash": "3kqGRmpS7oW", "uri": "/contracts/3kqGRmpS7oW#permitted-deductions", "label": "Contingent Value Rights Agreement (Cyclerion Therapeutics, Inc.)", "score": 37.2464065552, "published": true}, {"hash": "i4Z6aGrA2o", "uri": "/contracts/i4Z6aGrA2o#permitted-deductions", "label": "Contingent Value Rights Agreement (Rallybio Corp)", "score": 37.1642723083, "published": true}, {"hash": "kpYv1LLeMwj", "uri": "/contracts/kpYv1LLeMwj#permitted-deductions", "label": "Business Combination Agreement (Sonnet BioTherapeutics Holdings, Inc.)", "score": 36.9206008911, "published": true}], "size": 23, "hash": "cf8c1b2a74eb90bfb04936acc936359a", "id": 3}, {"snippet": "has the meaning set forth in Section 1.148.", "snippet_links": [], "samples": [{"hash": "kFCOvBekbUe", "uri": "/contracts/kFCOvBekbUe#permitted-deductions", "label": "License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)", "score": 35.3682403564, "published": true}, {"hash": "eZw8VhlZ7Ch", "uri": "/contracts/eZw8VhlZ7Ch#permitted-deductions", "label": "License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)", "score": 29.5776863098, "published": true}, {"hash": "1F7NiN3Blxq", "uri": "/contracts/1F7NiN3Blxq#permitted-deductions", "label": "License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)", "score": 29.353181839, "published": true}], "size": 14, "hash": "d5e214bbb0e0270b5fb4a5ec86d1286b", "id": 4}, {"snippet": "means: (i) funds received as consideration for equity purchases of Licensee\u2019s securities by a Sublicensee at the fair market value of such equities, (ii) payments received by Licensee from any Sublicensee for purposes of paying Licensee for any future research requested by the Sublicensee, for development, testing, or engineering services actually undertaken by or for Licensee related to any Licensed Product or Licensed Process. For greater clarity, payment by a Sublicensee for future research expenses incurred by or for Licensee after the Effective Date for research which has not been requested by Sublicensee and has been conducted by Licensee as Licensee\u2019s diligent pursuit of the Licensed Patents shall not be considered a Permitted Deduction.", "snippet_links": [{"key": "funds-received", "type": "clause", "offset": [11, 25]}, {"key": "equity-purchases", "type": "clause", "offset": [47, 63]}, {"key": "of-licensee", "type": "clause", "offset": [64, 75]}, {"key": "securities-by", "type": "definition", "offset": [78, 91]}, {"key": "the-fair-market-value", "type": "clause", "offset": [109, 130]}, {"key": "by-licensee", "type": "clause", "offset": [172, 183]}, {"key": "for-purposes-of", "type": "clause", "offset": [205, 220]}, {"key": "future-research", "type": "clause", "offset": [245, 260]}, {"key": "requested-by", "type": "definition", "offset": [261, 273]}, {"key": "the-sublicensee", "type": "clause", "offset": [274, 289]}, {"key": "for-development", "type": "clause", "offset": [291, 306]}, {"key": "engineering-services", "type": "clause", "offset": [320, 340]}, {"key": "for-licensee", "type": "definition", "offset": [367, 379]}, {"key": "related-to", "type": "clause", "offset": [380, 390]}, {"key": "licensed-product", "type": "definition", "offset": [395, 411]}, {"key": "licensed-process", "type": "definition", "offset": [415, 431]}, {"key": "for-greater-clarity", "type": "clause", "offset": [433, 452]}, {"key": "payment-by", "type": "clause", "offset": [454, 464]}, {"key": "expenses-incurred", "type": "definition", "offset": [499, 516]}, {"key": "after-the-effective-date", "type": "clause", "offset": [536, 560]}, {"key": "for-research", "type": "clause", "offset": [561, 573]}, {"key": "by-sublicensee", "type": "clause", "offset": [603, 617]}, {"key": "diligent-pursuit", "type": "clause", "offset": [667, 683]}, {"key": "licensed-patents", "type": "definition", "offset": [691, 707]}, {"key": "permitted-deduction", "type": "definition", "offset": [734, 753]}], "samples": [{"hash": "1BvPVivsnSI", "uri": "/contracts/1BvPVivsnSI#permitted-deductions", "label": "Standard Exclusive License Agreement (Myriant Corp)", "score": 22.6098556519, "published": true}, {"hash": "cwNlkrxTFNx", "uri": "/contracts/cwNlkrxTFNx#permitted-deductions", "label": "Standard Exclusive License Agreement (Myriant Corp)", "score": 22.4866523743, "published": true}, {"hash": "9kTDb8fPTL0", "uri": "/contracts/9kTDb8fPTL0#permitted-deductions", "label": "Standard Exclusive License Agreement (Myriant Corp)", "score": 22.4866523743, "published": true}], "size": 10, "hash": "f11cfc09bed8d231a5fa89cf291e4be9", "id": 5}, {"snippet": "means, to the extent not already excluded from Net Sales, the following deductions that are either included in the billing as a line item as part of the amount charged or invoiced, or otherwise documented as a deduction and accrued in accordance with GAAP specifically attributable to sales of the Product:", "snippet_links": [{"key": "to-the-extent", "type": "clause", "offset": [7, 20]}, {"key": "net-sales", "type": "clause", "offset": [47, 56]}, {"key": "line-item", "type": "clause", "offset": [128, 137]}, {"key": "in-accordance-with", "type": "clause", "offset": [232, 250]}, {"key": "the-product", "type": "definition", "offset": [294, 305]}], "samples": [{"hash": "d4oOHfBluEB", "uri": "/contracts/d4oOHfBluEB#permitted-deductions", "label": "Merger Agreement (Timber Pharmaceuticals, Inc.)", "score": 34.6344985962, "published": true}, {"hash": "4D7hpBkEPLd", "uri": "/contracts/4D7hpBkEPLd#permitted-deductions", "label": "Merger Agreement (Timber Pharmaceuticals, Inc.)", "score": 34.6344985962, "published": true}, {"hash": "h7Pa1ZUewrI", "uri": "/contracts/h7Pa1ZUewrI#permitted-deductions", "label": "Contingent Value Rights Agreement (Indivior PLC)", "score": 34.388092041, "published": true}], "size": 7, "hash": "783c66c67604b0dd66d3eef0cd85a075", "id": 6}, {"snippet": "shall have the meaning set forth in the definition of Net Sales.", "snippet_links": [{"key": "definition-of-net-sales", "type": "clause", "offset": [40, 63]}], "samples": [{"hash": "4MW7Qey7CHp", "uri": "/contracts/4MW7Qey7CHp#permitted-deductions", "label": "Research, Development, Collaboration and License Agreement (Assembly Biosciences, Inc.)", "score": 28.3483905792, "published": true}, {"hash": "bdwtXZ2oy7Y", "uri": "/contracts/bdwtXZ2oy7Y#permitted-deductions", "label": "License Agreement (Ventrus Biosciences Inc)", "score": 21.5475692749, "published": true}, {"hash": "lXbRJKOTsoN", "uri": "/contracts/lXbRJKOTsoN#permitted-deductions", "label": "Psma/PSMP License Agreement (Progenics Pharmaceuticals Inc)", "score": 21.0, "published": true}], "size": 7, "hash": "67b577a800aeae361aa411d70926ff85", "id": 7}, {"snippet": "means (i) amounts Parent is permitted to offset or set off pursuant to Section 11.5 of the Merger Agreement and (ii) amounts for which the Holder Representative (in his capacity as the Company Stockholder Representative under the Merger Agreement) is indemnified pursuant to Section 3.9(d) of the Merger Agreement.", "snippet_links": [{"key": "pursuant-to-section", "type": "clause", "offset": [59, 78]}, {"key": "the-merger-agreement", "type": "clause", "offset": [87, 107]}, {"key": "the-holder-representative", "type": "clause", "offset": [135, 160]}, {"key": "in-his-capacity-as", "type": "clause", "offset": [162, 180]}, {"key": "company-stockholder-representative", "type": "definition", "offset": [185, 219]}], "samples": [{"hash": "kikRgQfALa2", "uri": "/contracts/kikRgQfALa2#permitted-deductions", "label": "Merger Agreement (Telix Pharmaceuticals LTD)", "score": 35.7926063538, "published": true}, {"hash": "dP7vGqrEt0U", "uri": "/contracts/dP7vGqrEt0U#permitted-deductions", "label": "Merger Agreement (Telix Pharmaceuticals LTD)", "score": 35.6995201111, "published": true}, {"hash": "lEa1sKbmNrN", "uri": "/contracts/lEa1sKbmNrN#permitted-deductions", "label": "Merger Agreement (Telix Pharmaceuticals LTD)", "score": 35.3737182617, "published": true}], "size": 6, "hash": "ae498cb67bd96e57e77eae056f87a108", "id": 8}, {"snippet": "means funds received as consideration for equity purchases of LICENSEE\u2019S securities by a sublicense (provided that fair and commercially reasonable sublicense fees are collected in conjunction with such transaction) and any other payments received by LICENSEE from any sublicense for purposes of paying or reimbursing LICENSEE for any future research, development, testing, or engineering services actually undertaken by or for LICENSEE related to any Licensed Product or Licensed Process.", "snippet_links": [{"key": "funds-received", "type": "clause", "offset": [6, 20]}, {"key": "equity-purchases", "type": "clause", "offset": [42, 58]}, {"key": "of-licensee", "type": "clause", "offset": [59, 70]}, {"key": "securities-by", "type": "definition", "offset": [73, 86]}, {"key": "provided-that", "type": "definition", "offset": [101, 114]}, {"key": "commercially-reasonable", "type": "definition", "offset": [124, 147]}, {"key": "sublicense-fees", "type": "clause", "offset": [148, 163]}, {"key": "by-licensee", "type": "clause", "offset": [248, 259]}, {"key": "for-purposes-of", "type": "clause", "offset": [280, 295]}, {"key": "future-research", "type": "clause", "offset": [335, 350]}, {"key": "engineering-services", "type": "clause", "offset": [377, 397]}, {"key": "for-licensee", "type": "definition", "offset": [424, 436]}, {"key": "related-to", "type": "clause", "offset": [437, 447]}, {"key": "licensed-product", "type": "definition", "offset": [452, 468]}, {"key": "licensed-process", "type": "definition", "offset": [472, 488]}], "samples": [{"hash": "eRqqrOVpfat", "uri": "/contracts/eRqqrOVpfat#permitted-deductions", "label": "Standard Exclusive License Agreement (Myriant Corp)", "score": 22.6098556519, "published": true}, {"hash": "3Z7vMGxzpp7", "uri": "/contracts/3Z7vMGxzpp7#permitted-deductions", "label": "Standard Exclusive License Agreement (Myriant Corp)", "score": 22.6098556519, "published": true}, {"hash": "1jYsmjTZsGt", "uri": "/contracts/1jYsmjTZsGt#permitted-deductions", "label": "Standard Exclusive License Agreement (Myriant Corp)", "score": 22.6098556519, "published": true}], "size": 6, "hash": "faf92f4373c310b156c8304a70ae215b", "id": 9}, {"snippet": "means the following items, all in accordance with standard allocation procedures, allowance methodologies and accounting methods consistently applied in accordance with GAAP (except as otherwise provided below):", "snippet_links": [{"key": "in-accordance-with", "type": "clause", "offset": [31, 49]}, {"key": "allocation-procedures", "type": "clause", "offset": [59, 80]}, {"key": "accounting-methods", "type": "definition", "offset": [110, 128]}, {"key": "consistently-applied", "type": "definition", "offset": [129, 149]}, {"key": "except-as-otherwise-provided", "type": "clause", "offset": [175, 203]}], "samples": [{"hash": "iPsLxjz5VKW", "uri": "/contracts/iPsLxjz5VKW#permitted-deductions", "label": "Merger Agreement (Grail, LLC)", "score": 35.3436012268, "published": true}, {"hash": "jDOI2MJmlb0", "uri": "/contracts/jDOI2MJmlb0#permitted-deductions", "label": "Merger Agreement (Grail, LLC)", "score": 34.9411354065, "published": true}, {"hash": "dtYur25nxpz", "uri": "/contracts/dtYur25nxpz#permitted-deductions", "label": "Contingent Value Rights Agreement (Illumina, Inc.)", "score": 32.6276512146, "published": true}], "size": 6, "hash": "d8e9d05c8215f98adf07c577527ebd94", "id": 10}], "next_curs": "CmESW2oVc35sYXdpbnNpZGVyY29udHJhY3Rzcj0LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIdcGVybWl0dGVkLWRlZHVjdGlvbnMjMDAwMDAwMGEMogECZW4YACAA", "definition": {"snippet": "means the sum of, without duplication, the following costs or expenses:", "size": 289, "title": "Permitted Deductions", "id": "permitted-deductions", "examples": ["All reasonable and documented fees and expenses of any third-party proxy solicitor engaged by Parent in connection with the Parent Special Meeting shall constitute <strong>Permitted Deductions</strong>."], "related": [["permitted-distributions", "Permitted Distributions", "Permitted Distributions"], ["permitted-payments", "Permitted Payments", "Permitted Payments"], ["permitted-debt", "Permitted Debt", "Permitted Debt"], ["excluded-payments", "Excluded Payments", "Excluded Payments"], ["permitted-distribution", "Permitted Distribution", "Permitted Distribution"]], "related_snippets": [], "updated": "2026-04-18T05:49:41+00:00"}, "json": true, "cursor": ""}}